Dr. David L. Palchak, MD

Dr. Palchak practices at Pcr Oncology in Arroyo Grande, California.

Dr. Palchak's NPI, 1396815965, was assigned on November 9, 2006. Dr. Palchak graduated from Saint Louis University School Of Medicine in 1986. Dr. Palchak holds California license G60994.

Dr. Palchak's primary practice is Pcr Oncology, at 584 Camino Mercado, Arroyo Grande, CA 93420-1816. The practice phone is (805) 474-9143.

Dr. Palchak's primary practice is Pcr Oncology in Arroyo Grande, California. Dr. Palchak is also affiliated with Dignity Health - Marian Regional Medical Center. The medical group on file is PCR Oncology. Dmand AI also links Dr. Palchak to 1 more hospital and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Palchak practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Palchak's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Palchak is board certified in internal medicine by the American Board of Internal Medicine. Dr. Palchak is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), immune deficiency disease, lung cancer and lymphoma among the conditions Dr. Palchak treats.

CMS data shows 7,590 Medicare services from Dr. Palchak across 20 procedure codes in 2024, for 316 Medicare patients. Medicare paid $231,647 for them. Every service was in an office.

CMS counts 316 Medicare patients who saw Dr. Palchak in 2024. The largest group is 65 to 74, with 136 patients. 65% of them have high blood pressure, and 65% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.50, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Palchak's median patient age at 72, with 64% women.

In 2024, Dr. Palchak wrote 1,158 Medicare Part D claims for 185 patients. 72% of them were for generic drugs. CMS names the drug for 784 of them, across 33 drugs with 11 or more claims each, at $2,670,400 in total drug cost. In 2023, CMS named 770 claims across 32 drugs.

Dr. Palchak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Palchak as offering telehealth.

Dmand AI links 2 papers to Dr. Palchak. The most frequent topics are Antineoplastic Agents, Prostatic Neoplasms and Suramin. Dr. Palchak's most frequent co-author is Eric J. Small, MD.

Dmand AI links Dr. Palchak to 17 clinical trials, 9 of them phase 3 studies. 3 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Leukemia, Lymphocytic, Chronic, B-Cell. National Cancer Institute (NCI) sponsors the most, 7. Open Payments lists research payments to Dr. Palchak that name 1 trial.

CMS Open Payments shows 174 general payments to Dr. Palchak from 30 drug and device companies from 2016 to 2025. Gifts make up the largest share, 45% of the total. Novartis Pharmaceuticals Corporation paid the most, $4,903. It also lists 3 research payments totaling $15,770 from 2024 to 2025, naming 1 clinical trial.

Dr. Palchak graduated from Saint Louis University School Of Medicine in 1986.

Dr. Palchak is in network with 11 carriers, including Elevance, United Healthcare and Aetna. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.